# Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

> **NCT00291876** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 135 (actual)

## Conditions studied

- Hepatitis A

## Interventions

- **BIOLOGICAL:** Havrix™

## Key facts

- **NCT ID:** NCT00291876
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-01
- **Primary completion:** 2013-03-01
- **Final completion:** 2013-03-01
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2017-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291876, "Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00291876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*